• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

    10.63 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Telix Pharmaceuticals Limited - American Depositary Shares

    < Previous 1 2 3 4 Next >
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    TELIX INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Telix Pharmaceuticals Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Stockholders
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Telix Pharmaceuticals Enters Q4 On Strong Footing With Stabilized Pricing Pressures, Upgraded Annual Sales Guidance
    Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA imaging and reimbursement gains. 
    Via Benzinga
    Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    CMS Grants Transitional Pass-Through Status for Gozellix
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    TLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
    From The Rosen Law Firm PA
    Via GlobeNewswire
    Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
    From Pomerantz LLP
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Agilon, Albany International, Fluor, and Telix and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
    From Pomerantz LLP
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
    From Pomerantz LLP
    Via GlobeNewswire
    Telix Gets Second FDA Rejection For Kidney Cancer Drug
    FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities. 
    Via Benzinga
    Cooper Companies Posts Downbeat Sales, Joins NetApp, Urban Outfitters, Nvidia And Other Big Stocks Moving Lower In Thursday Pre-Market Session
     
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
     
    Via Benzinga
    Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Telix to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference and H.C. Wainwright 27th Annual Global Investment Conference
    From Telix Pharmaceuticals Limited
    Via GlobeNewswire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
    From Pomerantz LLP
    Via GlobeNewswire
    TELIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Telix Pharmaceuticals Limited on Behalf of Telix Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Rosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation – TLX
    From Rosen Law Firm
    Via Business Wire
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
    From Pomerantz LLP
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.